Inventiva Temporarily Suspends Trading on Euronext Paris
Inventiva has announced a temporary suspension of its stock trading on Euronext Paris due to a public offering in the United States.
Temporary Suspension of Trading
According to a press release from the biopharmaceutical company Inventiva, trading of its ordinary shares on the Euronext Paris market will be temporarily suspended starting at 9:00 AM (CET) today. This move is part of an exclusive public offering in the United States involving new American Depositary Shares (ADSs), each representing a new ordinary share of the company with a nominal value of 0.01 euros. The suspension is intended to allow for the confirmation of allocations and the announcement of the final terms of the offering.
Details of the U.S. Public Offering
The public offering is exclusively for the American market and is expected to result in the listing of the new ADSs on the Nasdaq Global Market under the symbol 'IVA', starting at 9:30 AM (ET). According to the release, the suspension on Euronext Paris is expected to end around 3:30 PM (CET), when trading of the ADSs may potentially begin on the Nasdaq.
Company Profile
Inventiva, listed on both Euronext Paris and the Nasdaq, specializes in the development of small molecules for the treatment of MASH. The company is currently evaluating lanifibranor in a phase 3 clinical study to treat this chronic liver disease.
